Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Colorectal Neoplasms

Free Subscription 04.03.2019 4 Ann Oncol 1 Ann Surg 3 Ann Surg Oncol 2 BMC Cancer 1 Br J Surg 1 Clin Cancer Res 1 Eur J Cancer 2 Gastrointest Endosc 1 Gut 1 J Am Coll Surg 1 J Natl Cancer Inst 7 J Surg Oncol 1 Lancet Oncol 8 Oncogene 2 Oncol Rep 1 Oncology (Williston Park) 1 PLoS Genet 3 PLoS One 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Ann Oncol

1. FONTANA E, Eason K, Cervantes A, Salazar R, et al
   Context Matters - Consensus Molecular Subtypes of Colorectal Cancer as Biomarkers for Clinical Trials.
   Ann Oncol. 2019 Feb 23. pii: 5364014. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
2. SINGH AV
   21PEvaluation of magnetic nanoparticle of irinotecan for personalized treatment of colorectal cancer.
   Ann Oncol. 2019;30.
   PubMed     Text format    
   
   
3. CAVIC M, Vidosavljevic M, Radulovic S, Grahovac J, et al
   20PNischarin expression in colon cancer.
   Ann Oncol. 2019;30.
   PubMed     Text format    
   
   
4. LEE CL, Toomey S, Farrelly A, Hennessy B, et al
   19PPreclinical drug testing and clinical trial planning of palbociclib (CDK4/6 inhibitor) drug combination with a PI3K or MAPK inhibitor for colorectal cancer (CRC).
   Ann Oncol. 2019;30.
   PubMed     Text format    
   
   

   
   Ann Surg

5. OKUGAWA Y, Toiyama Y, Yamamoto A, Shigemori T, et al
   Lymphocyte-C-reactive Protein Ratio as Promising New Marker for Predicting Surgical and Oncological Outcomes in Colorectal Cancer.
   Ann Surg. 2019 Feb 16. doi: 10.1097/SLA.0000000000003239.
   PubMed     Text format     Abstract available
   
   

   
   Ann Surg Oncol

6. SPINOGLIO G, Bianchi PP, Marano A, Priora F, et al
   Correction to: Robotic Versus Laparoscopic Right Colectomy with Complete Mesocolic Excision for the Treatment of Colon Cancer: Perioperative Outcomes and 5-Year Survival in a Consecutive Series of 202 Patients.
   Ann Surg Oncol. 2019 Feb 25. pii: 10.1245/s10434-019-07267.
   PubMed     Text format     Abstract available
   
   
7. KELLY KJ, Alsayadnasser M, Vaida F, Veerapong J, et al
   Does Primary Tumor Side Matter in Patients with Metastatic Colon Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy?
   Ann Surg Oncol. 2019 Feb 27. pii: 10.1245/s10434-019-07255.
   PubMed     Text format     Abstract available
   
   
8. HA GW, Kim JH, Lee MR
   Oncologic Effects of Primary Tumor-Sidedness on Patients with Stages 1-3 Colon Cancer: A Meta-Analysis.
   Ann Surg Oncol. 2019 Feb 25. pii: 10.1245/s10434-019-07164.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

9. KLEMENT RJ, Abbasi-Senger N, Adebahr S, Alheid H, et al
   The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases.
   BMC Cancer. 2019;19:173.
   PubMed     Text format     Abstract available
   
   
10. JI H, Lu L, Huang J, Liu Y, et al
    IL1A polymorphisms is a risk factor for colorectal cancer in Chinese Han population: a case control study.
    BMC Cancer. 2019;19:181.
    PubMed     Text format     Abstract available
    
    

    
    Br J Surg

11. ABIS GSA, Stockmann HBAC, Bonjer HJ, van Veenendaal N, et al
    Randomized clinical trial of selective decontamination of the digestive tract in elective colorectal cancer surgery (SELECT trial).
    Br J Surg. 2019;106:355-363.
    PubMed     Text format     Abstract available
    
    

    
    Clin Cancer Res

12. SIRAVEGNA G, Sartore-Bianchi A, Nagy RJ, Raghav K, et al
    Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer.
    Clin Cancer Res. 2019 Feb 26. pii: 1078-0432.CCR-18-3389.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Cancer

13. CASCINU S, Poli D, Zaniboni A, Lonardi S, et al
    The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials.
    Eur J Cancer. 2019;111:1-7.
    PubMed     Text format     Abstract available
    
    

    
    Gastrointest Endosc

14. PARK CH, Jung YS, Kim NH, Park JH, et al
    Usefulness of risk stratification models for colorectal cancer based on fecal hemoglobin concentration and clinical risk factors.
    Gastrointest Endosc. 2019 Feb 25. pii: S0016-5107(19)30138.
    PubMed     Text format     Abstract available
    
    
15. GRIMM IS, McGill SK
    Look, but don't touch: what not to do in managing large colorectal polyps.
    Gastrointest Endosc. 2019;89:479-481.
    PubMed     Text format    
    
    

    
    Gut

16. CHEUNG KS, Chen L, Chan EW, Seto WK, et al
    Statins reduce the progression of non-advanced adenomas to colorectal cancer: a postcolonoscopy study in 187 897 patients.
    Gut. 2019 Feb 26. pii: gutjnl-2018-317714. doi: 10.1136/gutjnl-2018-317714.
    PubMed     Text format     Abstract available
    
    

    
    J Am Coll Surg

17. GAN T, Sinner HF, Walling SC, Chen Q, et al
    Impact of the Affordable Care Act on Colorectal Cancer Screening, Incidence, and Survival in Kentucky.
    J Am Coll Surg. 2019 Jan 17. pii: S1072-7515(19)30046.
    PubMed     Text format     Abstract available
    
    

    
    J Natl Cancer Inst

18. CIVES M, Anaya DA, Soares H, Coppola D, et al
    Analysis of Postoperative Recurrence in Stage I-III Midgut Neuroendocrine Tumors.
    J Natl Cancer Inst. 2018;110:282-289.
    PubMed     Text format     Abstract available
    
    

    
    J Surg Oncol

19. SCLAFANI F, Hesselberg G, Thompson SR, Truskett P, et al
    Multimodality treatment of oligometastatic anal squamous cell carcinoma: A case series and literature review.
    J Surg Oncol. 2019;119:489-496.
    PubMed     Text format     Abstract available
    
    
20. CHAPMAN BC, Goodman K, Hosokawa P, Gleisner A, et al
    Improved survival in rectal cancer patients who are treated with long-course versus short-course neoadjuvant radiotherapy: A propensity-matched analysis of the NCDB.
    J Surg Oncol. 2019;119:518-531.
    PubMed     Text format     Abstract available
    
    
21. BLISS LA, Strong EA, Gamblin TC
    Surgical resectability of multisite metastatic colorectal cancer: Pushing the limits while appropriately selecting patients.
    J Surg Oncol. 2019 Feb 25. doi: 10.1002/jso.25419.
    PubMed     Text format     Abstract available
    
    
22. SANDHU J, Lavingia V, Fakih M
    Systemic treatment for metastatic colorectal cancer in the era of precision medicine.
    J Surg Oncol. 2019 Feb 25. doi: 10.1002/jso.25421.
    PubMed     Text format     Abstract available
    
    
23. MELSTROM LG, Tzeng CD
    Metastatic colorectal cancer: The reality of the present and the optimism of the future.
    J Surg Oncol. 2019 Feb 26. doi: 10.1002/jso.25427.
    PubMed     Text format    
    
    
24. LEE RM, Cardona K, Russell MC
    Historical perspective: Two decades of progress in treating metastatic colorectal cancer.
    J Surg Oncol. 2019 Feb 26. doi: 10.1002/jso.25431.
    PubMed     Text format     Abstract available
    
    
25. DE ANDRADE JP, Warner SG, Fong Y
    Treatment of metastatic colorectal cancer: innovations in surgical techniques.
    J Surg Oncol. 2019 Feb 27. doi: 10.1002/jso.25418.
    PubMed     Text format     Abstract available
    
    

    
    Lancet Oncol

26. KLEPPE A, Albregtsen F, Vlatkovic L, Pradhan M, et al
    Chromatin organisation and cancer prognosis: a pan-cancer study.
    Lancet Oncol. 2018;19:356-369.
    PubMed     Text format     Abstract available
    
    

    
    Oncogene

27. TAO Y, Liu Z, Hou Y, Wang S, et al
    Alternative NF-kappaB signaling promotes colorectal tumorigenesis through transcriptionally upregulating Bcl-3.
    Oncogene. 2018;37:5887-5900.
    PubMed     Text format     Abstract available
    
    
28. DANKNER M, Rose AAN, Rajkumar S, Siegel PM, et al
    Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
    Oncogene. 2018;37:3183-3199.
    PubMed     Text format     Abstract available
    
    
29. KOTELEVETS L, Walker F, Mamadou G, Lehy T, et al
    The Rac1 splice form Rac1b favors mouse colonic mucosa regeneration and contributes to intestinal cancer progression.
    Oncogene. 2018;37:6054-6068.
    PubMed     Text format     Abstract available
    
    
30. COBURN LA, Singh K, Asim M, Barry DP, et al
    Loss of solute carrier family 7 member 2 exacerbates inflammation-associated colon tumorigenesis.
    Oncogene. 2019;38:1067-1079.
    PubMed     Text format     Abstract available
    
    
31. HUANG X, Wang XN, Yuan XD, Wu WY, et al
    XIAP facilitates breast and colon carcinoma growth via promotion of p62 depletion through ubiquitination-dependent proteasomal degradation.
    Oncogene. 2019;38:1448-1460.
    PubMed     Text format     Abstract available
    
    
32. WANG T, Song P, Zhong T, Wang X, et al
    The inflammatory cytokine IL-6 induces FRA1 deacetylation promoting colorectal cancer stem-like properties.
    Oncogene. 2019 Feb 25. pii: 10.1038/s41388-019-0763.
    PubMed     Text format     Abstract available
    
    
33. SONG ZY, Wang F, Cui SX, Gao ZH, et al
    CXCR7/CXCR4 heterodimer-induced histone demethylation: a new mechanism of colorectal tumorigenesis.
    Oncogene. 2019;38:1560-1575.
    PubMed     Text format     Abstract available
    
    
34. SHIMIZU M, Tanaka N
    IL-8-induced O-GlcNAc modification via GLUT3 and GFAT regulates cancer stem cell-like properties in colon and lung cancer cells.
    Oncogene. 2018 Oct 10. pii: 10.1038/s41388-018-0533.
    PubMed     Text format     Abstract available
    
    

    
    Oncol Rep

35. XU J, Qian J, Zhang W, Chen E, et al
    LYPD8 regulates the proliferation and migration of colorectal cancer cells through inhibiting the secretion of IL6 and TNFalpha.
    Oncol Rep. 2019 Feb 26. doi: 10.3892/or.2019.7034.
    PubMed     Text format     Abstract available
    
    
36. JIANG Y, Cai Y, Shao W, Li F, et al
    MicroRNA144 suppresses aggressive phenotypes of tumor cells by targeting ANO1 in colorectal cancer.
    Oncol Rep. 2019 Feb 21. doi: 10.3892/or.2019.7025.
    PubMed     Text format     Abstract available
    
    

    
    Oncology (Williston Park)

37. WEISS J, Afghahi A, Shagisultanova E, Diamond JR, et al
    Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast Cancer.
    Oncology (Williston Park). 2018;32:513-5.
    PubMed     Text format    
    
    

    
    PLoS Genet

38. POULOS RC, Wong YT, Ryan R, Pang H, et al
    Analysis of 7,815 cancer exomes reveals associations between mutational processes and somatic driver mutations.
    PLoS Genet. 2018;14:e1007779.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

39. DOUMA LN, Uiters E, Timmermans DRM
    Do people with a different goal-orientation or specific focus make different decisions about colorectal cancer-screening participation?
    PLoS One. 2019;14:e0213003.
    PubMed     Text format     Abstract available
    
    
40. TSUTSUYAMA M, Nakanishi H, Yoshimura M, Oshiro T, et al
    Detection of circulating tumor cells in drainage venous blood from colorectal cancer patients using a new filtration and cytology-based automated platform.
    PLoS One. 2019;14:e0212221.
    PubMed     Text format     Abstract available
    
    
41. MAKONDI PT, Wei PL, Huang CY, Chang YJ, et al
    Development of novel predictive miRNA/target gene pathways for colorectal cancer distance metastasis to the liver using a bioinformatic approach.
    PLoS One. 2019;14:e0211968.
    PubMed     Text format     Abstract available
    
    

    
    Proc Natl Acad Sci U S A

42. 
    Correction for Rentoft et al., Heterozygous colon cancer-associated mutations of SAMHD1 have functional significance.
    Proc Natl Acad Sci U S A. 2019 Feb 25. pii: 1902081116.
    PubMed     Text format    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: